Arnaud Grandeury

This inventor holds 15 USPTO granted patents and 9 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Formulations. Top assignees: Novartis Ag, Cephalon, Inc., Teva Sante. Active years: 2014-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Arnaud Grandeury. Retrieved from https://idiyas.com/inventor/arnaud-grandeury

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 9)

% Patents Active = 73.3

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.2

ph-index = 2

Forward Citations = 15(Granted Patents)

Location History:

Basel, CH (2017 - 2020)
Helfrantzkirch, FR (2014 - 2024)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2014-2026

Loading Chart...

Areas of Expertise:

Pharmaceuticals

Ribociclib

Crystalline Forms

Benzothiazolone

Polymorphs

Hydrated Compounds

Pyrrolocarbazole

Formulations

Carboxylic Acid

Dimethylamide

Hydroxy

Preparation

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12653807 - Modified release formulation for (-)-(3AR,4S,7AR)-4-hydroxy-4-m-tolylethynyl-octahydro-indole-1-carboxylic acid methyl ester (2026-06-16),

2. 12419894 - Ribociclib tablet (2025-09-23),

3. 12390468 - Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide (2025-08-19),

4. 12252479 - Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide (2025-03-18),

5. 12252478 - Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide (2025-03-18),

6. 12064434 - Ribociclib tablet (2024-08-20),

7. 11407735 - Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide (2022-08-09),

8. 10934273 - Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino)benzothiazol-6-yloxy)-N-methylpicolinamide (2021-03-02),

9. 10799506 - Ribociclib tablet (2020-10-13),

10. 10251868 - Benzothiazolone compound (2019-04-09),

11. 9913828 - Benzothiazolone compound (2018-03-13),

12. 9623012 - Formulation comprising benzothiazolone compound (2017-04-18),

13. 8987448 - Preparation of anhydrous and hydrated polymorphs 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-YL)-1H-benzimidazol-2-YL]-1H-quinolin-2-one-lactic acid salt (2015-03-24),

14. 8933108 - Benzothiazolone compound (2015-01-13),

15. 8884014 - Method for purifying a fused pyrrolocarbazole derivative (2014-11-11),

Title: Arnaud Grandeury: Innovator in Pharmaceutical Patents

Introduction

Arnaud Grandeury is a notable inventor based in Helfrantzkirch, France. He has made significant contributions to the pharmaceutical industry, holding a total of 14 patents. His work primarily focuses on innovative drug formulations and delivery systems.

Latest Patents

One of Grandeury's latest patents is for a ribociclib tablet. This patent discloses an oral tablet formulation of ribociclib, including its salt(s). One embodiment of this patent describes a tablet with a high drug load and an immediate release profile. Additionally, he has developed a coated tablet of ribociclib, where the coating serves as an aqueous moisture barrier, specifically using Opadry® amb II coating, which is PVA-based. Furthermore, he has provided new crystalline forms of succinate salts of 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide, along with pharmaceutical compositions and methods of treatment utilizing these forms.

Career Highlights

Grandeury has worked with prominent companies in the pharmaceutical sector, including Novartis AG and Cephalon, Inc. His experience in these organizations has contributed to his expertise in drug development and patenting.

Collaborations

Throughout his career, Grandeury has collaborated with notable professionals in the field, including Robin Alec Fairhurst and Shinji Hatakeyama. These collaborations have likely enhanced his innovative capabilities and broadened his impact on pharmaceutical advancements.

Conclusion

Arnaud Grandeury is a distinguished inventor whose work in pharmaceutical patents has led to significant advancements in drug formulations. His contributions continue to influence the industry and improve treatment options for patients.

Profile summary based on public USPTO records.